BACKGROUND: Brain dysfunction in prefrontal cortex (PFC) and dorsal striatum (DS) contributes to habitual drug use. These regions are constituents of brain networks thought to be involved in drug addiction. To investigate whether networks containing these regions differ between nicotine dependent female smokers and age-matched female non-smokers, we employed functional MRI (fMRI) at rest. METHODS: Data were processed with independent component analysis (ICA) to identify resting state networks (RSNs). We identified a subcortical limbic network and three discrete PFC networks: a medial prefrontal cortex (mPFC) network and right and left lateralized fronto-parietal networks common to all subjects. We then compared these RSNs between smokers and non-smokers using a dual regression approach. RESULTS: Smokers had greater coupling versus non-smokers between left fronto-parietal and mPFC networks. Smokers with the greatest mPFC-left fronto-parietal coupling had the most DS smoking cue reactivity as measured during an fMRI smoking cue reactivity paradigm. This may be important because the DS plays a critical role in maintaining drug-cue associations. Furthermore, subcortical limbic network amplitude was greater in smokers. CONCLUSIONS: Our results suggest that prefrontal brain networks are more strongly coupled in smokers, which could facilitate drug-cue responding. Our data also are the first to document greater reward-related network fMRI amplitude in smokers. Our findings suggest that resting state PFC network interactions and limbic network amplitude can differentiate nicotine-dependent smokers from controls, and may serve as biomarkers for nicotine dependence severity and treatment efficacy.
BACKGROUND:Brain dysfunction in prefrontal cortex (PFC) and dorsal striatum (DS) contributes to habitual drug use. These regions are constituents of brain networks thought to be involved in drug addiction. To investigate whether networks containing these regions differ between nicotine dependent female smokers and age-matched female non-smokers, we employed functional MRI (fMRI) at rest. METHODS: Data were processed with independent component analysis (ICA) to identify resting state networks (RSNs). We identified a subcortical limbic network and three discrete PFC networks: a medial prefrontal cortex (mPFC) network and right and left lateralized fronto-parietal networks common to all subjects. We then compared these RSNs between smokers and non-smokers using a dual regression approach. RESULTS: Smokers had greater coupling versus non-smokers between left fronto-parietal and mPFC networks. Smokers with the greatest mPFC-left fronto-parietal coupling had the most DS smoking cue reactivity as measured during an fMRI smoking cue reactivity paradigm. This may be important because the DS plays a critical role in maintaining drug-cue associations. Furthermore, subcortical limbic network amplitude was greater in smokers. CONCLUSIONS: Our results suggest that prefrontal brain networks are more strongly coupled in smokers, which could facilitate drug-cue responding. Our data also are the first to document greater reward-related network fMRI amplitude in smokers. Our findings suggest that resting state PFC network interactions and limbic network amplitude can differentiate nicotine-dependent smokers from controls, and may serve as biomarkers for nicotine dependence severity and treatment efficacy.
Authors: Nicola Filippini; Bradley J MacIntosh; Morgan G Hough; Guy M Goodwin; Giovanni B Frisoni; Stephen M Smith; Paul M Matthews; Christian F Beckmann; Clare E Mackay Journal: Proc Natl Acad Sci U S A Date: 2009-04-08 Impact factor: 11.205
Authors: Stephen M Smith; Peter T Fox; Karla L Miller; David C Glahn; P Mickle Fox; Clare E Mackay; Nicola Filippini; Kate E Watkins; Roberto Toro; Angela R Laird; Christian F Beckmann Journal: Proc Natl Acad Sci U S A Date: 2009-07-20 Impact factor: 11.205
Authors: Justin L Vincent; Itamar Kahn; Abraham Z Snyder; Marcus E Raichle; Randy L Buckner Journal: J Neurophysiol Date: 2008-09-17 Impact factor: 2.714
Authors: Amy C Janes; Blaise deB Frederick; Sarah Richardt; Caitlin Burbridge; Emilio Merlo-Pich; Perry F Renshaw; A Eden Evins; Maurizio Fava; Marc J Kaufman Journal: Exp Clin Psychopharmacol Date: 2009-12 Impact factor: 3.157
Authors: L Elliot Hong; Hong Gu; Yihong Yang; Thomas J Ross; Betty Jo Salmeron; Brittany Buchholz; Gunvant K Thaker; Elliot A Stein Journal: Arch Gen Psychiatry Date: 2009-04
Authors: Amy C Janes; Stacey Farmer; Alyssa L Peechatka; Blaise de B Frederick; Scott E Lukas Journal: Neuropsychopharmacology Date: 2015-01-08 Impact factor: 7.853
Authors: Luke E Stoeckel; Xiaoqian J Chai; Jiahe Zhang; Susan Whitfield-Gabrieli; A Eden Evins Journal: Addict Biol Date: 2015-05-20 Impact factor: 4.280
Authors: Kathleen A Garrison; Rajita Sinha; Cheryl M Lacadie; Dustin Scheinost; Ania M Jastreboff; R Todd Constable; Marc N Potenza Journal: Nicotine Tob Res Date: 2016-03-19 Impact factor: 4.244
Authors: Maggie M Sweitzer; Charles F Geier; Merideth A Addicott; Rachel Denlinger; Bethany R Raiff; Jesse Dallery; F Joseph McClernon; Eric C Donny Journal: Neuropsychopharmacology Date: 2016-04-19 Impact factor: 7.853
Authors: Megan M Moran-Santa Maria; Karen J Hartwell; Colleen A Hanlon; Melanie Canterberry; Todd Lematty; Max Owens; Kathleen T Brady; Mark S George Journal: Addict Biol Date: 2014-02-13 Impact factor: 4.280
Authors: José M Martínez-Ortega; Benjamin I Goldstein; Luis Gutiérrez-Rojas; Regina Sala; Shuai Wang; Carlos Blanco Journal: J Psychiatr Res Date: 2013-04-11 Impact factor: 4.791